Who this guide is for
This guide is for medtech manufacturers, start-ups and clinical or regulatory leads choosing a contract research organisation to run a clinical investigation, a performance study or a post-market clinical follow-up programme for a medical device or in vitro diagnostic. If you are looking for the best medical device CRO, the right answer depends on your device class, your target markets and the evidence gap your notified body or regulator has raised. The ranked list above is a starting point for discovery, not a verdict on which vendor will suit your clinical investigation plan; the ranked profiles do not list medical devices among their therapeutic areas, so the table and device profiles below are the more relevant place to start. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score. Use the criteria below to test fit before you shortlist.
What a medical device CRO does — and when you need one
A medical device CRO plans and runs clinical investigations under ISO 14155, the good clinical practice standard for devices, rather than ICH E6(R3), which governs medicinal product trials. Typical work spans early feasibility and first-in-human studies, pivotal investigations that support conformity assessment, and post-market studies. Deliverables include the clinical investigation plan (CIP), investigator’s brochure, site training, monitoring, device accountability, safety and device deficiency reporting, data management and the clinical investigation report. Many also support regulatory submissions and clinical evaluation writing.
A regulatory consultancy may write your clinical evaluation report without running any sites. A notified body assesses your technical documentation independently and is not permitted to act as your consultant. A preclinical laboratory handles bench and biocompatibility testing before human use. Drug CROs can run device studies, but their processes are usually built around phases and medicinal products rather than device iterations.
You typically need a device CRO when an equivalence route closes under the EU MDR, when a notified body asks for more clinical data, when your PMCF plan calls for a dedicated study, or when you enter the US under an investigational device exemption (21 CFR Part 812).
How to evaluate a medical device CRO
ISO 14155 fluency
Ask how the CRO’s SOPs map to ISO 14155, including risk-based monitoring, CIP content and sponsor oversight duties. Request a redacted monitoring plan and a sample CIP from a comparable device. Be wary of teams that use drug vocabulary throughout; it often signals processes adapted late rather than built for devices.
EU MDR and IVDR evidence strategy
A capable partner should explain how the investigation feeds your clinical evaluation under Article 61 and Annex XIV of MDR 2017/745, or your performance evaluation under IVDR 2017/746. Ask how they approach equivalence, state of the art, and the link between endpoints, intended purpose and the claims you plan to make.
UK MHRA and UKCA experience
For a medical device CRO UK sponsors can rely on, check recent MHRA clinical investigation notifications, IRAS submissions and research ethics committee reviews. Ask how the team tracks the GB framework under the UK Medical Devices Regulations 2002, including UKCA marking, the GB post-market surveillance requirements and Northern Ireland’s separate position under the Windsor Framework.
Competent authority and notified body interface
Competent authorities and ethics committees decide whether an investigation may proceed; notified bodies assess the resulting evidence during conformity assessment. Ask who prepares Article 70 applications in each member state, how the CRO handles requests for information, and whether it has supported files that went through the clinical evaluation consultation procedure with expert panels.
Device-specific monitoring and safety reporting
Device monitoring covers accountability and traceability by lot or serial number, procedure-day observation, deviations linked to technique, and classification of adverse device effects, serious adverse device effects and device deficiencies. Ask for the safety management plan and how reportable events reach competent authorities under MDR Article 80.
Investigator training and device handling
Investigators and site staff need documented training on the device, the CIP and deficiency reporting, often including hands-on or proctored cases. Ask how training is recorded, how roll-in or learning-curve cases are treated in the analysis, and how manufacturer field staff are kept from influencing data during procedures.
Data, imaging and core labs
Many device endpoints depend on imaging, physiological signals or device logs. Ask whether the EDC meets 21 CFR Part 11 and UK and EU GDPR expectations, how device-generated data is reconciled, and which imaging core labs the CRO has worked with.
PMCF and post-market delivery
Post-market clinical follow-up under Annex XIV Part B is a continuous obligation, not a single study. Ask how the CRO designs PMCF plans and evaluation reports, runs registries or surveys, and feeds findings into the periodic safety update report and summary of safety and clinical performance where these apply. Under the IVDR, the equivalent is post-market performance follow-up.
Medical device CRO vendors at a glance
The table below lists vendors in this category whose profiles mention devices, medtech or diagnostics in their vendor type, service model or therapeutic areas. Use it to narrow a long list by footprint, delivery model and stated focus.
Fields shown are taken from each vendor’s Clinical Vendor Compare profile.
| Vendor | Vendor type | Service model | Geography | Study phases | Therapeutic areas |
|---|
| Tigermed |
Full-service CRO |
Full Service CRO |
Asia / Global (HQ: China) |
Mixed |
Oncology, Rare Disease, Medical Devices |
| MedTrials Research |
Specialist CRO |
Specialist CRO |
North America (HQ: USA) |
Phase I, Phase II, Phase III |
Medical Devices |
| Aixial Group |
Specialist CRO |
Full Service CRO |
Global (HQ: France) |
Mixed |
Oncology, Cell & Gene Therapy, Medical Devices, Generalist |
| ClinChoice |
Full-service CRO |
Full Service CRO |
Global (HQ: USA) |
Mixed |
Generalist, Medical Devices & Diagnostics |
| NAMSA |
Full-service CRO |
Specialist CRO |
Global (HQ: USA) |
Mixed |
Medical Devices |
| Qserve Regulatory & QA |
Specialist CRO |
Specialist CRO |
Europe / Global (HQ: Netherlands) |
Phase I, Phase II, Phase III, Phase IV |
Medical Devices, Diagnostics |
| AtoZ-CRO |
Specialist CRO |
Full Service CRO |
Europe / USA / India / Global (HQ: Germany) |
Phase I, Phase II, Phase III, Phase IV |
Generalist, Medical Devices |
| Avania |
Specialist CRO |
Specialist CRO |
Global (HQ: Netherlands) |
Mixed |
Medical Devices, Diagnostics, Combination Products, Oncology & Radiology, Aesthetics & Dermatology |
| ClinDatrix |
Full-service CRO |
Specialist CRO |
Global (HQ: USA) |
Mixed |
Medical Devices |
| Veranex |
Full-service CRO |
Specialist CRO |
Global (HQ: USA) |
Mixed |
Medical Devices |
Every field comes from each vendor’s Clinical Vendor Compare profile. Note that many device-focused vendors record their phases as mixed; device investigations are usually described as feasibility, pivotal or post-market rather than by drug phase, so ask each vendor which stages it covers. Geography ranges from North America to Asia and global coverage, and some generalist CROs list devices alongside other areas. A device listing tells you about stated focus, not ISO 14155 depth, so verify that separately.
Vendor profiles
Tigermed is recorded as a full-service CRO headquartered in China with Asia and global coverage, mixed phases, and areas spanning oncology, rare disease and medical devices. Its profile describes large Asia and global programmes, with strengths in clinical trial management, regulatory affairs and site management, and its stated fit is sponsors seeking Asia and global coverage. Where to probe: ask for UK and EU device investigations run under ISO 14155 and who owns MDR competent authority submissions.
MedTrials Research is a US-based specialist CRO with North America coverage, Phase I to Phase III listed, and medical devices as its only recorded area. The profile describes focused North American studies for trials needing focused expertise or complex operational handling, citing expert focus, flexibility and domain depth. Where to probe: its profile names very large global programmes needing maximal scale as a limitation, so test European or UK site capacity early.
Aixial Group is recorded as a specialist CRO with a full-service model, headquartered in France with global coverage and mixed phases. Its areas include oncology, cell and gene therapy, medical devices and generalist work at mid-size to large scale. The profile positions it for specialist coverage spanning clinical operations, consulting and FSP support in complex therapy areas. Where to probe: ask how much of its device work runs under ISO 14155.
ClinChoice is listed as a full-service CRO headquartered in the USA with global coverage, mixed phases and a generalist profile that also names medical devices and diagnostics. Its record describes specialist and mid-size global programmes, with strengths in clinical development, post-marketing, functional service support and full-service outsourcing, which may suit sponsors weighing full-service against functional models. Where to probe: ask for PMCF examples and who writes the evaluation reports.
NAMSA is recorded with a full-service CRO type and a specialist service model, headquartered in the USA with global coverage and mixed phases. Medical devices is its only listed area, across specialist and mid-size global programmes. Stated strengths are medical device clinical research and regulatory consulting, which may suit sponsors wanting both from one device-focused provider. Where to probe: ask how independence is kept when regulatory and clinical teams touch the same evidence.
Qserve Regulatory & QA is a specialist CRO headquartered in the Netherlands with Europe and global coverage, listing Phase I to Phase IV and focusing on medical devices and diagnostics. Its profile points to work needing filings, compliance, inspection readiness or QA support, citing regulatory know-how and compliance frameworks. Where to probe: its profile notes it is often best used with clear scope, milestones and document ownership, so agree document owners before contracting.
AtoZ-CRO is recorded as a specialist CRO with a full-service model, headquartered in Germany with coverage across Europe, the USA, India and global markets. It lists Phase I to Phase IV and pairs generalist work with medical devices, citing expert focus, flexibility and domain depth for trials needing complex operational handling. Where to probe: its profile flags very large global programmes needing maximal scale as a limitation, so confirm resourcing for a multi-country pivotal study.
Avania is a specialist CRO headquartered in the Netherlands with global coverage and mixed phases, covering medical devices, diagnostics, combination products, oncology and radiology, and aesthetics and dermatology. The profile positions it for medtech, diagnostics and combination-product sponsors that want a specialist rather than a generalist, citing device-heavy specialisation. Where to probe: for combination products, ask how it reconciles ISO 14155 and ICH E6(R3) obligations in a single plan.
ClinDatrix is recorded with a full-service CRO type and a specialist service model, headquartered in the USA with global coverage and mixed phases. Medical devices is its only listed area, across specialist and mid-size global programmes, and its profile names device clinical trials, regulatory support and data management as its focus. Where to probe: ask how device logs and imaging are reconciled with the EDC, and which UK and EU investigations it has supported.
Veranex is recorded with a full-service CRO type and a specialist service model, headquartered in the USA with global coverage, mixed phases and medical devices as its listed area. Its record describes specialist and mid-size global programmes, with strengths in device clinical research and regulatory consulting, which may suit sponsors wanting clinical and regulatory work from one provider. Where to probe: ask for named investigation leads with UK and EU ISO 14155 experience.
Engagement and pricing models
Most sponsors buy device clinical work as a full-service investigation, as functional support for monitoring, data management or safety, or as a hybrid that pairs a specialist device CRO with a separate regulatory consultancy. PMCF registries and surveys are often priced on a unit basis per site or per enrolled participant, while pivotal investigations are quoted as a full budget with pass-through costs.
The main cost drivers are site count and geography, monitoring intensity, procedure-day attendance, device accountability visits, imaging or core lab reads, the number of competent authority and ethics submissions, and regulatory writing such as clinical evaluation reports and PMCF plans. Device design changes mid-study trigger CIP amendments and retraining, so ask how change orders are priced. Integrated regulatory and clinical delivery reduces handovers but concentrates risk with a single vendor; a split model adds coordination cost but keeps an independent eye on the evidence.
Questions to put in your RFP
- Which of your SOPs were written for ISO 14155 rather than adapted from drug GCP?
- Who on the proposed team has run investigations in our device class and clinical area?
- How will you prepare and track Article 70 applications across member states and the MHRA notification in Great Britain?
- How do you classify and escalate serious adverse events, serious adverse device effects and device deficiencies, and who reports them?
- How do you train and document investigators on device handling, and how are roll-in cases managed?
- Can you share a redacted PMCF plan and evaluation report, and explain how it updated the clinical evaluation report?
- How do you handle design or software changes mid-investigation?
- Which imaging core labs have you integrated with your EDC?
- How do you manage independence if your regulatory consultants and clinical team both work on our file?
- For UK sites, how do you manage IRAS, research ethics committee review and NHS capacity?
Due-diligence red flags
- Proposals that use drug terms such as "protocol" and "IMP" throughout and never mention the CIP or device deficiencies.
- No clear owner for competent authority applications or their follow-up questions.
- Claims that a notified body will approve your clinical investigation.
- Monitoring plans with no device accountability or procedure-observation component.
- Equivalence presented as an easy route for an implantable or class III device, with no discussion of MDR constraints.
- PMCF treated as a single study rather than a continuous plan tied to your ISO 14971 risk management file.
- Outdated UK advice, such as treating Great Britain and Northern Ireland as one market.
- Manufacturer field staff given site roles without controls on data entry or influence.
- Training records that are generic slides with no device-specific competence check.
Shortlist on Clinical Vendor Compare
Start in the vendor directory, narrow by category and region, and open profiles to check footprint, service model and stated focus. Whether you need a CRO for medtech UK investigations or a global pivotal study, add candidates to compare to view them side by side. When you are ready, use the sponsor RFP to send a structured brief built from the questions above. If you have worked with a device CRO, please write a review; honest accounts of investigations help other sponsors choose well.
